PeptideDB

PrNMI

CAS: 1541244-33-0 F: C29H31NO W: 409.56

PrNMI is a potent and orally active agonist of peripherally restricted cannabinoid 1 receptor (CB1R). PrNMI suppresses c
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity PrNMI is a potent and orally active agonist of peripherally restricted cannabinoid 1 receptor (CB1R). PrNMI suppresses chemotherapy-induced peripheral neuropathy pain symptoms and also acts as an analgesic in cancer-induced bone pain[1][2].
Invitro PrNMI (1 nM-1 μM; 24 hours) shows no effects on viability of 66.1 breast tumor cells in vitro[2]. Cell Viability Assay[2] Cell Line:
In Vivo PrNMI (0.25 mg/kg; Intraplantar ipsilateral administration; i.p.) causes significantly greater suppression in mechanical but not cold allodynia on the ipsilateral paw compared to contralateral paw or systemic administration at 2 h post-PrNMI[1].PrNMI (3.0 mg/kg; i.g.; 48 hours) dose-dependently suppresses CIPN symptoms in both male and female rats and is equally effective in male and female rats after oral administration[1].PrNMI (1 mg/kg; p.o.; 48 hours) exhibits anti-allodynic effects in CIPN mediated mainly by CB1Rs[1].PrNMI (1 mg/kg; p.o.; daily for two weeks) shows no significant tolerance to suppression of both mechanical and cold allodynia during the two-week testing period[1].PrNMI (0.1, 0.3, and 0.6 mg/kg; i.p.) results in a significant, time-related reduction of flinching but not guarding in a dose-dependent manner. This suppression of flinching starts 1-hour post-injection and persists for at least 5 hours[2]. Animal Model:
Name PrNMI
CAS 1541244-33-0
Formula C29H31NO
Molar Mass 409.56
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Mulpuri Y, et al. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropharmacology. 2018;139:85-97. [2]. Zhang H, et al. Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Pain. 2018;159(9):1814-1823.